The Gap, Inc. SEC Filings

The Form 4 filed on 2 July 2025 reports insider activity by Robert J. Fisher, a Director and 10 % owner of The Gap, Inc. (NYSE: GPS). All transactions occurred on 30 June 2025.

• 20,631 common shares issued upon settlement of previously granted stock units at a $0 exercise price.
• 2,572 common shares issued from dividend-equivalent rights, also at no cost.
• 25,500 common shares disposed under a Rule 10b5-1 trading plan adopted 18 March 2025 (code “G”).

Post-transaction direct ownership stands at 12,970,433 shares. Indirect holdings remain: 132,257 shares by spouse, 3,329,502 shares in trust, and 22,015,000 shares via limited partnerships.

The filing corrects a prior typographical error, revising the balance of dividend-equivalent rights to 1,225.8949 units.

The net direct change is a reduction of 2,297 shares, an immaterial amount relative to Fisher’s aggregate stake and Gap’s share count. No cash was exchanged for acquired shares, reflecting equity-compensation vesting rather than open-market buying.

Rocket Companies, Inc. (RKT) filed a Form 4 disclosing that Chief Operating Officer Heather M. Lovier received a substantial equity grant as part of the company’s Up-C collapse completed on 30 June 2025. The restructuring exchanged each Rock Holdings Inc. voting share for 56.54 newly issued Rocket Class L shares, split evenly between Class L-1 and Class L-2.

• Lovier acquired 1,413,489 Class L-1 and 1,413,490 Class L-2 shares (total ≈ 2.83 million) at $0.00 cost, all held directly.
• Transfer restrictions apply: L-1 shares are non-transferable before 30 June 2026; L-2 before 30 June 2027.
• After the respective lock-ups, each Class L share may be converted, or will automatically convert upon transfer, into one share of Rocket Class A common stock. A mass conversion occurs once Class L voting power drops below 79 % after the later of the two key dates.
• Lovier now reports 642,740 Class A shares (including 421,126 unvested RSUs) in addition to the new Class L holdings.

The filing signals completion of a capital-structure simplification and updates the insider’s beneficial ownership; it does not record any sale of securities, cash compensation, or option exercises.

Form 4 filing for KORU Medical Systems, Inc. (KRMD) discloses that director Shahriar Matin acquired 4,189 shares of common stock on 07/02/2025 at a reported price of $3.58 per share. Following the transaction, Matin’s direct ownership increased to 87,604 shares. No derivative security activity or additional explanatory notes beyond the standard boiler-plate language were provided. The filing was signed by Attorney-in-Fact Thomas Adams.

On 07/01/2025, Gartner Inc. (IT) filed a Form 4 disclosing that outside director Jose M. Gutierrez converted 32 Common Stock Equivalents (CSEs) into an equal number of Gartner common shares at $0 cost. The distribution was made under the company’s Long-Term Incentive Plan (LTIP) and is coded “J,” indicating an ‘other’ type of transaction. Immediately before the conversion, Gutierrez received a routine LTIP grant of 32 additional CSEs priced at $406.70 per unit (Code “A”), leaving him with 226 CSEs outstanding after the offsetting distribution.
Following the reported transactions, the director’s direct ownership stands at 1,663 common shares plus the remaining 226 CSEs. The 32-share increase represents an immaterial fraction of Gartner’s ~80 million diluted shares outstanding and does not affect the public float or corporate control. The filing reflects ordinary, compensation-related equity movements rather than a discretionary open-market purchase or sale, and therefore has limited signaling value for investors.

Form 4 Filing: Director Michael A. Woronoff acquired 585 shares of Alexandria Real Estate Equities, Inc. (ARE) common stock on 06/30/2025 at an acquisition price of $0, indicating a board stock grant rather than an open-market purchase. After the grant, Woronoff directly owns 20,107 shares and indirectly controls 1,400 shares through a trust, for a total beneficial ownership of 21,507 shares.

No dispositions or derivative security transactions were reported and the filing makes no reference to a Rule 10b5-1 trading plan. On a company level, the 585-share issuance represents less than 0.001 % of ARE’s roughly 173 million shares outstanding—far below any dilution threshold—so the transaction is not financially material. Nonetheless, the incremental ownership increase modestly improves director–shareholder alignment.

Lincoln National Corp. (LNC) – Form 4 insider filing

On 06/30/2025, director Owen Ryan received 2,167.63 Phantom Stock Units (transaction code A) under the company’s Deferred Compensation Plan for Non-Employee Directors. Each phantom unit is economically equivalent to one share of common stock and will be settled in shares when the director resigns or retires. The award represents the quarterly payment of board retainer and fees, not an open-market purchase. Following the transaction Ryan now beneficially owns 17,647.89 phantom units, including 214.87 units acquired via dividend reinvestment since his last filing. The units were credited at an accounting price of $34.60 per share. Ownership is reported as direct (D).

No non-derivative share transactions were reported, and there is no indication of sales or option exercises. The filing reflects routine director compensation rather than a discretionary investment, implying limited market impact but modestly increasing alignment between the director and shareholders.

Arcutis Biotherapeutics (ARQT) filed a Form 4 disclosing that director Howard G. Welgus sold 9,208 common shares on 01 July 2025 at a weighted-average price of $13.8391 (price range: $13.65–$13.99). The sale was executed under a Rule 10b5-1 trading plan adopted on 11 March 2025 and scheduled to run through 29 May 2026.

Following the transaction, Welgus still beneficially owns 100,206 shares, held directly. No derivative security activity was reported. The filing was signed on 02 July 2025 by an attorney-in-fact.

This single transaction represents a modest reduction in the director’s holdings and does not, by itself, provide information on company fundamentals or near-term performance; however, investors often monitor insider sales for sentiment signals.

ZoomInfo Technologies Inc. (ZI) – Form 144 filing discloses a planned insider sale under Rule 144.

• Securities to be sold: 14,773 Class A common shares.
• Estimated market value: US$148,911.84 (based on prevailing market price cited in the form).
• Seller of record: James M. Roth, acting pursuant to a Rule 10b5-1 trading plan, with Morgan Stanley Smith Barney LLC as broker.
• Planned sale date: on or about 02 July 2025 through NASDAQ.
• Share-count context: ZI reports 328,911,200 shares outstanding; the proposed sale represents ≈0.0045 % of shares outstanding.
• Recent activity: The same insider sold 18,408 shares on 05 June 2025 for gross proceeds of US$184,398.72.

The filing is a routine notice rather than a completed transaction. Given the small size relative to total float, the event is unlikely to be materially impactful for shareholders, but it does provide visibility into insider trading activity and possible sentiment.

Dyadic International, Inc. (Nasdaq: DYAI) filed a Form 8-K on 2 July 2025 to disclose a branding update. In 30 days the company will begin operating under the business name “Dyadic Applied BioSolutions.” The filing clarifies that the legal corporate name remains “Dyadic International, Inc.,” the DYAI ticker is unchanged, and the company will continue to trade on the Nasdaq Stock Market. The disclosure is provided under Item 7.01 (Regulation FD) and is furnished—not filed—thereby carrying no Section 18 liability and no direct impact on financial statements. No financial data, operational revisions, or strategic transactions are included; the report solely communicates the forthcoming DBA designation and furnishes the related press release as Exhibit 99.1.